Skip to Main Content

Paper Details

A multicenter, phase II trial of GC1118, a novel anti-EGFR antibody, for recurrent glioblastoma patients with EGFR amplification.
Cancer Med
4
2023
CEP7, EGFR, GBM, GC1118, Skin rash, anti-EGFR antibody, anti-epidermal growth factor receptor, immune, patients, recorded cells, recurrent glioblastoma, skin, tumor, tumors
Author NameAffiliation
Seung Won ChoiSungkyunkwan University, Samsung Medical Center
Hee Jin ChoKyungpook National University
Chul-Kee ParkSeoul National University Hospital, College of Medicine
Do-Hyun NamSungkyunkwan University, Samsung Medical Center
Do-Hyun NamSungkyunkwan University, Samsung Medical Center
  • 1 - 5

Datasets

Release 1.2